Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 5:8:583879.
doi: 10.3389/fbioe.2020.583879. eCollection 2020.

Nano-Biomaterials for the Delivery of Therapeutic and Monitoring Cues for Aortic Diseases

Shichao Zhu  1   2 , Kai Zhu  1   2 , Jun Li  1   2 , Hao Lai  1   2 , Chunsheng Wang  1   2
Affiliations
Review

Nano-Biomaterials for the Delivery of Therapeutic and Monitoring Cues for Aortic Diseases

Shichao Zhu et al. Front Bioeng Biotechnol. .

Abstract

The aorta is the largest artery in the body, so any diseases or conditions which could cause damage to the aorta would put patients at considerable and life-threatening risk. In the management of aortic diseases, the major treatments include drug therapy, endovascular treatment, and surgical treatment, which are of great danger or with a poor prognosis. The delivery of nano-biomaterials provides a potential development trend and an emerging field where we could monitor patients' conditions and responses to the nanotherapeutics. One of the putative applications of nanotechnology is ultrasensitive monitoring of cardiovascular markers by detecting and identifying aneurysms. Moreover, the use of nanosystems for targeted drug delivery can minimize the systemic side effects and enhance drug positioning and efficacy compared to conventional drug therapies. This review shows some examples of utilizing nano-biomaterials in in vitro organ and cell culture experiments and explains some developing technologies in delivering and monitoring regenerative therapeutics.

Keywords: aortic diseases; drug delivery; nano-biomaterials; regeneration; therapeutics.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Animal models of aortic aneurysms. (A) NP accumulation after intravenous injection of EL-NP-DIR, 30 days after injury at the site of elastin damage. (B) Representative picture showing targeting to degraded elastin. (C) Accumulation of rapamycin nanoparticles in the AAA rat model. (D) Localization of EL-GNPs within aneurysmal tissues. Color arrows and arrowheads refers to the stronger signal was found in the B1 which showed more elastin damage (C1) than the control section (B2) that contained only intact elastin fibers (C2).
See this image and copyright information in PMC

References

    1. Abdulameer H., Al Taii H., Al-Kindi S. G., Milner R. (2019). Epidemiology of fatal ruptured aortic aneurysms in the United States (1999-2016). J. Vasc. Surg. 69 378.e2–384.e2. 10.1016/j.jvs.2018.03.435 - DOI - PubMed
    1. Ashammakhi N., Ahadian S., Darabi M. A., El Tahchi M., Lee J., Suthiwanich K., et al. (2019). Minimally invasive and regenerative therapeutics. Adv. Mater. 31:e1804041. 10.1002/adma.201804041 - DOI - PMC - PubMed
    1. Au M., Emeto T. I., Power J., Vangaveti V. N., Lai H. C. (2016). Emerging therapeutic potential of nanoparticles in pancreatic cancer: a systematic review of clinical trials. Biomedicines 4:20. 10.3390/biomedicines4030020 - DOI - PMC - PubMed
    1. Baliga R. R., Nienaber C. A., Bossone E., Oh J. K., Isselbacher E. M., Sechtem U., et al. (2014). The role of imaging in aortic dissection and related syndromes. JACC Cardiovasc. Imaging 7 406–424. 10.1016/j.jcmg.2013.10.015 - DOI - PubMed
    1. Barisione C., Charnigo R., Howatt D. A., Moorleghen J. J., Rateri D. L., Daugherty A. (2006). Rapid dilation of the abdominal aorta during infusion of angiotensin II detected by noninvasive high-frequency ultrasonography. J. Vasc. Surg. 44 372–376. - PubMed

LinkOut - more resources